|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 28231 |
FusionGeneSummary for PPM1D_CCND1 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: PPM1D_CCND1 | Fusion gene ID: 28231 | Hgene | Tgene | Gene symbol | PPM1D | CCND1 | Gene ID | 8493 | 595 |
| Gene name | protein phosphatase, Mg2+/Mn2+ dependent 1D | cyclin D1 | |
| Synonyms | IDDGIP|PP2C-DELTA|WIP1 | BCL1|D11S287E|PRAD1|U21B31 | |
| Cytomap | 17q23.2 | 11q13.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | protein phosphatase 1Dprotein phosphatase 1D magnesium-dependent, delta isoformprotein phosphatase 2C delta isoformprotein phosphatase Wip1wild-type p53-induced phosphatase 1 | G1/S-specific cyclin-D1B-cell CLL/lymphoma 1B-cell lymphoma 1 proteinBCL-1 oncogenePRAD1 oncogene | |
| Modification date | 20180519 | 20180527 | |
| UniProtAcc | O15297 | P24385 | |
| Ensembl transtripts involved in fusion gene | ENST00000305921, | ENST00000227507, ENST00000536559, | |
| Fusion gene scores | * DoF score | 6 X 4 X 3=72 | 10 X 10 X 4=400 |
| # samples | 5 | 10 | |
| ** MAII score | log2(5/72*10)=-0.526068811667588 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(10/400*10)=-2 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: PPM1D [Title/Abstract] AND CCND1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | PPM1D | GO:0035970 | peptidyl-threonine dephosphorylation | 20801214 |
| Tgene | CCND1 | GO:0000082 | G1/S transition of mitotic cell cycle | 19412162 |
| Tgene | CCND1 | GO:0000122 | negative regulation of transcription by RNA polymerase II | 16569215|18417529 |
| Tgene | CCND1 | GO:0001934 | positive regulation of protein phosphorylation | 8114739 |
| Tgene | CCND1 | GO:0006974 | cellular response to DNA damage stimulus | 19412162 |
| Tgene | CCND1 | GO:0010971 | positive regulation of G2/M transition of mitotic cell cycle | 19124461 |
| Tgene | CCND1 | GO:0031571 | mitotic G1 DNA damage checkpoint | 19412162 |
| Tgene | CCND1 | GO:0044321 | response to leptin | 17344214 |
| Tgene | CCND1 | GO:0045737 | positive regulation of cyclin-dependent protein serine/threonine kinase activity | 8114739 |
| Tgene | CCND1 | GO:0070141 | response to UV-A | 18483258 |
| Tgene | CCND1 | GO:0071157 | negative regulation of cell cycle arrest | 19124461 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | BRCA | TCGA-BH-A18R-01A | PPM1D | chr17 | 58725443 | + | CCND1 | chr11 | 69466942 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-3UTR | ENST00000305921 | ENST00000227507 | PPM1D | chr17 | 58725443 | + | CCND1 | chr11 | 69466942 | + |
| 5CDS-intron | ENST00000305921 | ENST00000536559 | PPM1D | chr17 | 58725443 | + | CCND1 | chr11 | 69466942 | + |
Top |
FusionProtFeatures for PPM1D_CCND1 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| PPM1D | CCND1 |
| Involved in the negative regulation of p53 expression(PubMed:23242139). Required for the relief of p53-dependentcheckpoint mediated cell cycle arrest. Binds to anddephosphorylates 'Ser-15' of TP53 and 'Ser-345' of CHEK1 whichcontributes to the functional inactivation of these proteins(PubMed:15870257, PubMed:16311512). Mediates MAPK14dephosphorylation and inactivation (PubMed:21283629). Is also animportant regulator of global heterochromatin silencing andcritical in maintaining genome integrity (By similarity).{ECO:0000250|UniProtKB:Q9QZ67, ECO:0000269|PubMed:15870257,ECO:0000269|PubMed:16311512, ECO:0000269|PubMed:21283629,ECO:0000269|PubMed:23242139}. | Regulatory component of the cyclin D1-CDK4 (DC) complexthat phosphorylates and inhibits members of the retinoblastoma(RB) protein family including RB1 and regulates the cell-cycleduring G(1)/S transition. Phosphorylation of RB1 allowsdissociation of the transcription factor E2F from the RB/E2Fcomplex and the subsequent transcription of E2F target genes whichare responsible for the progression through the G(1) phase.Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4complexes are major integrators of various mitogenenic andantimitogenic signals. Also substrate for SMAD3, phosphorylatingSMAD3 in a cell-cycle-dependent manner and repressing itstranscriptional activity. Component of the ternary complex, cyclinD1/CDK4/CDKN1B, required for nuclear translocation and activity ofthe cyclin D-CDK4 complex. Exhibits transcriptional corepressoractivity with INSM1 on the NEUROD1 and INS promoters in a cellcycle-independent manner. {ECO:0000269|PubMed:15241418,ECO:0000269|PubMed:16569215, ECO:0000269|PubMed:18417529,ECO:0000269|PubMed:9106657}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for PPM1D_CCND1 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for PPM1D_CCND1 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| PPM1D | CDC5L, MDM2, H2AFX, RAD21, UBC, KDM1A, BEX2, CASZ1, DIRAS3, DKK3, EPSTI1, ERRFI1, GLCE, ITIH5, LYPD3, MRC2, NAT2, OSGIN1, RHOBTB2, WHSC1L1, KPNA2, KPNA3, KPNB1, NUP153, PSMD4, RANBP2, SPAG9, CHEK2 | CCND1 | AR, HDAC3, AKAP8, THRB, THRA, KAT2B, NEUROD1, EP300, CDK4, CDK6, CDKN2A, TAF1, CCNDBP1, RB1, HERC5, CDKN1C, CDKN1B, ESR1, RBX1, STAT3, TSC2, NPDC1, NCOA3, NCOA1, RFC1, PCNA, BRCA1, XPO1, CDKN1A, INSM1, HSPA8, HDAC1, HDAC2, MAPK11, WDR77, PRMT5, MAPK1, SKP1, CUL1, CUL7, FBXW8, FBXO4, CRYAB, FBXO31, ARID4A, USP2, UHRF2, SP1, CDK1, MCM7, MCM2, MCM3, MCM6, ELAVL1, ITLN1, PSMA6, CDK2, PPP1CB, PPP1CC, CCND1, ATF2, BTRC, RBL2, UBTF, CARD11, ORC4, MCM10, TP73, CAMK1, BRINP1, LPL, RABEP1, POLR1B, RELA, NXF1, BCAS3, CDH13, KLK7, KLK9, RANBP9, SLC25A5, ATP2B1, BTD, REV3L, GSK3B, MDM2, TP53, PSMD7, CDC27, FZR1, DTNBP1, CDKN2C, TCHH, CDK5, TSR3, TRIM25, NR1H3 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for PPM1D_CCND1 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | CCND1 | P24385 | DB01169 | Arsenic trioxide | G1/S-specific cyclin-D1 | small molecule | approved|investigational |
Top |
RelatedDiseases for PPM1D_CCND1 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | PPM1D | C0017638 | Glioma | 1 | CTD_human |
| Hgene | PPM1D | C0677866 | Brain Stem Neoplasms | 1 | CTD_human |
| Tgene | CCND1 | C1458155 | Mammary Neoplasms | 6 | CTD_human |
| Tgene | CCND1 | C2239176 | Liver carcinoma | 5 | CTD_human |
| Tgene | CCND1 | C0009375 | Colonic Neoplasms | 4 | CTD_human |
| Tgene | CCND1 | C0024667 | Animal Mammary Neoplasms | 4 | CTD_human |
| Tgene | CCND1 | C0024668 | Mammary Neoplasms, Experimental | 3 | CTD_human |
| Tgene | CCND1 | C0007621 | Neoplastic Cell Transformation | 2 | CTD_human |
| Tgene | CCND1 | C0020507 | Hyperplasia | 2 | CTD_human |
| Tgene | CCND1 | C0024121 | Lung Neoplasms | 2 | CTD_human |
| Tgene | CCND1 | C0334634 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | 2 | CTD_human;ORPHANET |
| Tgene | CCND1 | C0001418 | Adenocarcinoma | 1 | CTD_human |
| Tgene | CCND1 | C0006118 | Brain Neoplasms | 1 | CTD_human |
| Tgene | CCND1 | C0007137 | Squamous cell carcinoma | 1 | CTD_human |
| Tgene | CCND1 | C0007138 | Carcinoma, Transitional Cell | 1 | CTD_human |
| Tgene | CCND1 | C0007528 | Cecal Neoplasms | 1 | CTD_human |
| Tgene | CCND1 | C0007873 | Uterine Cervical Neoplasm | 1 | CTD_human |
| Tgene | CCND1 | C0010606 | Adenoid Cystic Carcinoma | 1 | CTD_human |
| Tgene | CCND1 | C0014859 | Esophageal Neoplasms | 1 | CTD_human |
| Tgene | CCND1 | C0018923 | Hemangiosarcoma | 1 | CTD_human |
| Tgene | CCND1 | C0020502 | Hyperparathyroidism | 1 | CTD_human |
| Tgene | CCND1 | C0021846 | Intestinal Polyps | 1 | CTD_human |
| Tgene | CCND1 | C0022665 | Kidney Neoplasm | 1 | CTD_human |
| Tgene | CCND1 | C0023418 | leukemia | 1 | CTD_human |
| Tgene | CCND1 | C0023903 | Liver neoplasms | 1 | CTD_human |
| Tgene | CCND1 | C0026764 | Multiple Myeloma | 1 | CTD_human;ORPHANET |
| Tgene | CCND1 | C0027659 | Neoplasms, Experimental | 1 | CTD_human |
| Tgene | CCND1 | C0030354 | Papilloma | 1 | CTD_human |
| Tgene | CCND1 | C0032927 | Precancerous Conditions | 1 | CTD_human |
| Tgene | CCND1 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Tgene | CCND1 | C0036095 | Salivary Gland Neoplasms | 1 | CTD_human |
| Tgene | CCND1 | C0036341 | Schizophrenia | 1 | PSYGENET |
| Tgene | CCND1 | C0038356 | Stomach Neoplasms | 1 | CTD_human |
| Tgene | CCND1 | C0040136 | Thyroid Neoplasm | 1 | CTD_human |
| Tgene | CCND1 | C0041696 | Unipolar Depression | 1 | PSYGENET |
| Tgene | CCND1 | C0042076 | Urologic Neoplasms | 1 | CTD_human |
| Tgene | CCND1 | C0151744 | Myocardial Ischemia | 1 | CTD_human |
| Tgene | CCND1 | C0279626 | Squamous cell carcinoma of esophagus | 1 | CTD_human |
| Tgene | CCND1 | C0919532 | Genomic Instability | 1 | CTD_human |
| Tgene | CCND1 | C1269683 | Major Depressive Disorder | 1 | PSYGENET |
| Tgene | CCND1 | C2931822 | Nasopharyngeal carcinoma | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|